Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs)

No abstract is available for this paper.

• Publication year

  2017

• Venue

  European journal of drug metabolism and pharmacokinetics

• Publication date

  2017-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s13318-016-0383-9PMID 27858342
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug-drug interactions.

  2016cited by this paper
• Mechanistic understanding of the nonlinear pharmacokinetics and intersubject variability of simeprevir: A PBPK‐guided drug development approach

  2016cited by this paper
• Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model

  2015cited by this paper
• Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective

  2015cited by this paper
• Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin

  2014cited by this paper
• Risks and Benefits of Statin Use in Young People with Type 1 Diabetes

  2014cited by this paper
• Deciding on Success Criteria for Predictability of Pharmacokinetic Parameters from In Vitro Studies: An Analysis Based on In Vivo Observations

  2014cited by this paper
• Towards Quantitation of the Effects of Renal Impairment and Probenecid Inhibition on Kidney Uptake and Efflux Transporters, Using Physiologically Based Pharmacokinetic Modelling and Simulations

  2014cited by this paper
• Predicting carrier-mediated hepatic disposition of rosuvastatin in man by scaling from individual transfected cell-lines in vitro using absolute transporter protein quantification and PBPK modeling.

  2014cited by this paper
• Toward Prospective Prediction of Pharmacokinetics in OATP1B1 Genetic Variant Populations

  2014cited by this paper
• Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.

  2014cited by this paper
• Fluoxetine and norfluoxetine mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19 and CYP3A4

  2014cited by this paper
• Long-lasting inhibitory effects of saquinavir and ritonavir on OATP1B1-mediated uptake.

  2013cited by this paper
• Substrate-Dependent Inhibition of Organic Anion Transporting Polypeptide 1B1: Comparative Analysis with Prototypical Probe Substrates Estradiol-17β-Glucuronide, Estrone-3-Sulfate, and Sulfobromophthalein

  2013influential reference
• Substrate-Dependent Ligand Inhibition of the Human Organic Cation Transporter OCT2

  2013cited by this paper
• Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption.

  2013cited by this paper
• Quantitative Prediction of Repaglinide-Rifampicin Complex Drug Interactions Using Dynamic and Static Mechanistic Models: Delineating Differential CYP3A4 Induction and OATP1B1 Inhibition Potential of Rifampicin

  2013cited by this paper
• A Mechanistic Framework for In Vitro–In Vivo Extrapolation of Liver Membrane Transporters: Prediction of Drug–Drug Interaction Between Rosuvastatin and Cyclosporine

  2013influential reference
• Structure-Based Identification of OATP1B1/3 Inhibitors

  2013cited by this paper
• Substrate-Dependent Inhibition of Human MATE1 by Cationic Ionic Liquids

  2013cited by this paper
• ITC Recommendations for Transporter Kinetic Parameter Estimation and Translational Modeling of Transport‐Mediated PK and DDIs in Humans

  2013cited by this paper
• Mechanistic Modeling to Predict the Transporter- and Enzyme-Mediated Drug-Drug Interactions of Repaglinide

  2013cited by this paper
• Effect of a single-dose rifampin on the pharmacokinetics of pitavastatin in healthy volunteers

  2013cited by this paper
• Predicting Drug Interaction Potential With a Physiologically Based Pharmacokinetic Model: A Case Study of Telithromycin, a Time‐Dependent CYP3A Inhibitor

  2012cited by this paper
• Statin drug interactions and related adverse reactions

  2012cited by this paper
• Understanding the Critical Disposition Pathways of Statins to Assess Drug–Drug Interaction Risk During Drug Development: It's Not Just About OATP1B1

  2012cited by this paper
• Mechanistic Pharmacokinetic Modeling for the Prediction of Transporter-Mediated Disposition in Humans from Sandwich Culture Human Hepatocyte Data

  2012cited by this paper
• Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions

  2012influential reference
• Differential Modulation of Cytochrome P450 Activity and the Effect of 1-Aminobenzotriazole on Hepatic Transport in Sandwich-Cultured Human Hepatocytes

  2012cited by this paper
• Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover.

  2011cited by this paper
• Effect of Gemfibrozil and Fenofibrate on the Pharmacokinetics of Atorvastatin

  2011cited by this paper
• Identification of the Rate‐Determining Process in the Hepatic Clearance of Atorvastatin in a Clinical Cassette Microdosing Study

  2011cited by this paper
• Physiologically Based Pharmacokinetic Modeling of Intestinal First-Pass Metabolism of CYP3A Substrates with High Intestinal Extraction

  2011cited by this paper
• Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability Data

  2010cited by this paper
• Investigation of the Rate-Determining Process in the Hepatic Elimination of HMG-CoA Reductase Inhibitors in Rats and Humans

  2010cited by this paper
• Selection of Alternative CYP3A4 Probe Substrates for Clinical Drug Interaction Studies Using In Vitro Data and In Vivo Simulation

  2010cited by this paper
• Cyclosporine A, but Not Tacrolimus, Shows Relevant Inhibition of Organic Anion-Transporting Protein 1B1-Mediated Transport of Atorvastatin

  2010influential reference
• No clinically relevant drug–drug interactions when dalcetrapib is co-administered with atorvastatin

  2010cited by this paper
• Population-Based Mechanistic Prediction of Oral Drug Absorption

  2009cited by this paper
• ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin

  2009cited by this paper
• Prediction of the Pharmacokinetics of Atorvastatin, Cerivastatin, and Indomethacin Using Kinetic Models Applied to Isolated Rat Hepatocytes

  2008cited by this paper
• The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15

  2008cited by this paper
• The Quantitative Prediction of CYP-mediated Drug Interaction by Physiologically Based Pharmacokinetic Modeling

  2008cited by this paper
• SLCO1B1 (OATP1B1, an Uptake Transporter) and ABCG2 (BCRP, an Efflux Transporter) Variant Alleles and Pharmacokinetics of Pitavastatin in Healthy Volunteers

  2007cited by this paper
• Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin

  2007cited by this paper
• Effect of OATP1B Transporter Inhibition on the Pharmacokinetics of Atorvastatin in Healthy Volunteers

  2007cited by this paper
• Use of Hepatocytes to Assess the Contribution of Hepatic Uptake to Clearance in Vivo

  2007cited by this paper
• Age-Related Differences in the Prevalence of Potential Drug-Drug Interactions in Ambulatory Dyslipidaemic Patients Treated with Statins

  2007cited by this paper
• Mechanistic Approaches to Volume of Distribution Predictions: Understanding the Processes

  2007cited by this paper
• Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.

  2006cited by this paper
• DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP1B1

  2006cited by this paper
• Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions.

  2006influential reference
• Drug interactions with lipid‐lowering drugs: Mechanisms and clinical relevance

  2006cited by this paper
• Statin safety and drug interactions: clinical implications.

  2006cited by this paper
• Tissue distribution of basic drugs: accounting for enantiomeric, compound and regional differences amongst beta-blocking drugs in rat.

  2005cited by this paper
• Human Hepatobiliary Transport of Organic Anions Analyzed by Quadruple-Transfected Cells

  2005cited by this paper
• Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells

  2005cited by this paper
• Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites

  2005influential reference
• Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases.

  2005influential reference
• Effect of Gemfibrozil on the Metabolism of Pitavastatin - Determining the Best Animal Model for Human CYP And UGT Activities

  2004cited by this paper
• Clinical Pharmacokinetics of Atorvastatin

  2003cited by this paper
• Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization

  2003cited by this paper
• Polymorphisms in OATP-C

  2001cited by this paper
• Bilateral Pharmacokinetic Interaction Between Cyclosporine A and Atorvastatin in Renal Transplant Recipients

  2001cited by this paper
• Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin.

  2000cited by this paper
• Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin

  2000cited by this paper
• Atorvastatin Transport in the Caco-2 Cell Model: Contributions of P-Glycoprotein and the Proton-Monocarboxylic Acid Co-Transporter

  2000cited by this paper
• Erythromycin Coadministration Increases Plasma Atorvastatin Concentrations

  1999influential reference
• Membrane transport in hepatic clearance of drugs. I: Extended hepatic clearance models incorporating concentration-dependent transport and elimination processes.

  1997cited by this paper
• Membrane Transport in Hepatic Clearance of Drugs I: Extended Hepatic Clearance Models Incorporating Concentration-Dependent Transport and Elimination Processes

  1997cited by this paper
• Tolerance and Pharmacokinetics of Single‐Dose Atorvastatin, a Potent Inhibitor of HMG‐CoA Reductase, in Healthy Subjects

  1996cited by this paper
• Clinical Pharmacokinetics in Organ Transplant Patients

  1989cited by this paper
• The Clinical Pharmacology of SQ 31,000 (CS 514) in Healthy Subjects

  1987cited by this paper

• Assessment of Potential Drug–Drug Interactions for Novel Oral Melanocortin‐1 Receptor Agonist Dersimelagon

  2025cites this paper
• Development of a Physiologically Based Pharmacokinetic Model to Evaluate Dosing Regimens of Cyclosporine as a Precipitant of Organic Anion Transporting Polypeptide 1B (OATP1B)‐ and CYP3A4‐Mediated Drug–Drug Interactions

  2025cites this paper
• Strategies to Improve Pharmacokinetics of Hepatic Uptake Transporter Substrates.

  2025cites this paper
• Determination of the latent geometry of atorvastatin pharmacokinetics by transfer entropy to identify bottlenecks

  2025cites this paper
• Genotype, Ethnicity, and Drug–Drug Interaction Modeling as Means of Verifying Transporter Biomarker PBPK Model: The Coproporphyrin‐I Story

  2025cites this paper
• Evaluation of Luteolin Nanosuspensions on Pharmacokinetics of Atorvastatin: Drug-Drug Interactions Using Rat Models

  2025cites this paper
• A Sequential Ultrafiltration Method to Enhance the Accuracy and Throughput in Plasma Protein Binding Tests

  2025cites this paper
• Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration

  2024cites this paper
• Drug transporters in drug disposition – highlights from the year 2023

  2024cites this paper
• PRT to predict pharmacokinetic profiles as part of a bioequivalence study of the drug deferasirox

  2024cites this paper
• Mechanistic Account of Distinct Change in Organic Anion Transporting Polypeptide 1B (OATP1B) Substrate Pharmacokinetics during OATP1B-Mediated Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling

  2024cites this paper
• Rifampin- and Silymarin-Mediated Pharmacokinetic Interactions of Exogenous and Endogenous Substrates in a Transgenic OATP1B Mouse Model.

  2024cites this paper
• Building a Predictive PBPK Model for Human OATP Substrates: a Strategic Framework for Early Evaluation of Clinical Pharmacokinetic Variations Using Pitavastatin as an Example

  2024influential citation
• Developing a mechanistic understanding of the nonlinear pharmacokinetics of letermovir and prospective drug interaction with everolimus using physiological‐based pharmacokinetic modeling

  2023cites this paper
• In silico prediction of bioequivalence of atorvastatin tablets based on GastroPlus™ software

  2023cites this paper
• Mechanistic Static Model based Prediction of Transporter Substrate Drug-Drug Interactions Utilizing Atorvastatin and Rifampicin

  2023cites this paper
• Utilization of OATP1B Biomarker Coproporphyrin‐I to Guide Drug–Drug Interaction Risk Assessment: Evaluation by the Pharmaceutical Industry

  2023cites this paper
• Drug transporters in drug disposition – the year 2022 in review

  2023cites this paper
• Pharmacokinetic and Pharmacodynamic Drug–Drug Interactions: Research Methods and Applications

  2023influential citation
• Use of In Vivo Imaging and Physiologically-Based Kinetic Modelling to Predict Hepatic Transporter Mediated Drug–Drug Interactions in Rats

  2023cites this paper
• Effect of a Ketohexokinase Inhibitor (PF‐06835919) on In Vivo OATP1B Activity: Integrative Risk Assessment Using Endogenous Biomarker and a Probe Drug

  2022cites this paper
• Effect of Hepatic Impairment on OATP1B Activity: Quantitative Pharmacokinetic Analysis of Endogenous Biomarker and Substrate Drugs

  2022cites this paper
• A physiologically based pharmacokinetic model for open acid and lactone forms of atorvastatin and metabolites to assess the drug-gene interaction with SLCO1B1 polymorphisms.

  2022cites this paper
• Itraconazole-Induced Increases in Gilteritinib Exposure Are Mediated by CYP3A and OATP1B

  2022cites this paper
• In Vitro Assessment of Transporter Mediated Perpetrator DDIs for Several Hepatitis C Virus Direct-Acting Antiviral Drugs and Prediction of DDIs with Statins Using Static Models

  2022cites this paper
• Cynomolgus Monkey as an Emerging Animal Model to Study Drug Transporters: In Vitro, In Vivo, In Vitro-to-In Vivo Translation

  2021cites this paper
• Evaluation of the drug–drug interaction potential for trazpiroben (TAK-906), a D2/D3 receptor antagonist for gastroparesis, towards cytochrome P450s and transporters

  2021cites this paper
• Improving the Translation of Organic Anion Transporting Polypeptide Substrates using HEK293 Cell Data in the Presence and Absence of Human Plasma via Physiologically Based Pharmacokinetic Modeling

  2021influential citation
• Current Evidence, Challenges, and Opportunities of Physiologically Based Pharmacokinetic Models of Atorvastatin for Decision Making

  2021cites this paper
• Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism

  2021cites this paper
• Biomarker‐Informed Model‐Based Risk Assessment of Organic Anion Transporting Polypeptide 1B Mediated Drug‐Drug Interactions

  2021cites this paper
• Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling

  2021cites this paper
• Physiologically based pharmacokinetic (PBPK) modelling of tamsulosin related to CYP2D6*10 allele

  2021cites this paper
• Atorvastatin population pharmacokinetics in a real‐life setting: Influence of genetic polymorphisms and association with clinical response

  2021cites this paper
• Physiologically based pharmacokinetic (PBPK) modeling of meloxicam in different CYP2C9 genotypes

  2021cites this paper
• Physiologically based pharmacokinetic modeling of candesartan related to CYP2C9 genetic polymorphism in adult and pediatric patients

  2021cites this paper
• Effects of CYP2C9*3 and *13 alleles on the pharmacokinetics and pharmacodynamics of glipizide in healthy Korean subjects

  2021cites this paper
• Multi-factorial pharmacokinetic interactions: unraveling complexities in precision drug therapy

  2020cites this paper
• Systemic Lupus Erythematosus Activity Affects the Sinusoidal Uptake Transporter OATP1B1 Evaluated by the Pharmacokinetics of Atorvastatin

  2020cites this paper
• PBPK model reporting template for chemical risk assessment applications

  2020cites this paper
• Static Model–Based Assessment of OATP1B1-Mediated Drug Interactions with Preincubation-Dependent Inhibitors Based on Inactivation and Recovery Kinetics

  2020cites this paper
• Prediction of Cyclosporin-Mediated Drug Interaction Using Physiologically Based Pharmacokinetic Model Characterizing Interplay of Drug Transporters and Enzymes

  2020cites this paper
• Utilization of Physiologically Based Pharmacokinetic Modeling in Clinical Pharmacology and Therapeutics: an Overview

  2020cites this paper
• Physiologically‐Based Pharmacokinetic Model‐Informed Drug Development for Fenebrutinib: Understanding Complex Drug‐Drug Interactions

  2020cites this paper
• In Vitro Hepatic Uptake in Human and Monkey Hepatocytes in the Presence and Absence of Serum Protein and Its In Vitro to In Vivo Extrapolation

  2020cites this paper
• Prediction of Transporter-Mediated Drug-Drug Interactions and Phenotyping of Hepatobiliary Transporters Involved in the Clearance of E7766, a Novel Macrocycle-Bridged Dinucleotide

  2020cites this paper
• Non-clinical Models to Determine Drug Passage into Human Breast Milk.

  2019cites this paper
• Statins: Adverse reactions, oxidative stress and metabolic interactions

  2019cites this paper
• Physiologically‐Based Pharmacokinetic Modeling of Atorvastatin Incorporating Delayed Gastric Emptying and Acid‐to‐Lactone Conversion

  2019cites this paper
• Theoretical consideration of the properties of intestinal flow models on route‐dependent drug removal: Segregated Flow (SFM) vs. Traditional (TM)

  2019cites this paper
• Bottom-up physiologically-based biokinetic modelling as an alternative to animal testing.

  2019cites this paper
• PBPK models for evaluating membrane transporter mediated DDIs: Current capabilities, case studies, future opportunities and recommendations.

  2019cites this paper
• Prediction of pharmacokinetic drug-drug interactions causing atorvastatin-induced rhabdomyolysis using physiologically based pharmacokinetic modelling.

  2019cites this paper
• Quantitative Prediction of OATP‐Mediated Drug‐Drug Interactions With Model‐Based Analysis of Endogenous Biomarker Kinetics

  2018cites this paper
• Relationships of Changes in Pharmacokinetic Parameters of Substrate Drugs in Drug–Drug Interactions on Metabolizing Enzymes and Transporters

  2018cites this paper
• Physiologically‐based pharmacokinetic modelling of a CYP2C19 substrate, BMS‐823778, utilizing pharmacogenetic data

  2018cites this paper
• Prediction and Quantification of Hepatic Transporter-Mediated Uptake of Pitavastatin Utilizing a Combination of the Relative Activity Factor Approach and Mechanistic Modeling

  2018influential citation
• Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium

  2018cites this paper
• Predikering av interaksjonen mellom atorvastatin og ciklosporin (CsA) ved bruk av en PBPK-modell (Simcyp)

  2018cites this paper
• Assessment of OATP transporter‐mediated drug–drug interaction using physiologically‐based pharmacokinetic (PBPK) modeling – a case example

  2018cites this paper
• A Strategy to Refine the Phenotyping Approach and Its Implementation to Predict Drug Clearance: A Physiologically Based Pharmacokinetic Simulation Study

  2018cites this paper
• In silico models in drug development: where we are

  2018cites this paper
• When Does the Rate-Determining Step in the Hepatic Clearance of a Drug Switch from Sinusoidal Uptake to All Hepatobiliary Clearances? Implications for Predicting Drug-Drug Interactions

  2018cites this paper
• Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Effect of Chronic Kidney Disease on the Disposition of Hepatic CYP2C8 and OATP1B Drug Substrates

  2018cites this paper
• Effects of medicines used to treat gastrointestinal diseases on the pharmacokinetics of coadministered drugs: a PEARRL Review

  2018cites this paper
• Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug–Drug Interaction Between Clopidogrel and Dasabuvir

  2017cites this paper
• Prediction of drug–drug interaction potential using physiologically based pharmacokinetic modeling

  2017influential citation
• Pretreatment With Rifampicin and Tyrosine Kinase Inhibitor Dasatinib Potentiates the Inhibitory Effects Toward OATP1B1- and OATP1B3-Mediated Transport.

  2017cites this paper
• Evaluation of transporters in drug development: Current status and contemporary issues☆

  2017cites this paper